Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05264506 · ClinicalTrials.gov registry record · Phase 3
Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
A Phase 3 study, sponsored by Organon and.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3,055
- Enrollment target
NCT05264506 is a Phase 3 study that was terminated before completion, run by Organon and. The registered enrollment target is 3,055 participants.
The verdict
NCT05264506, a Phase 3 study, was terminated before completion, sponsored by Organon and.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3,055 participants
- Enrollment target
Study Summary
The purpose of this study is evaluating Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive in Premenopausal Females Aged 14 to 35 Years (Inclusive).
Interventions
- DRUG NOMAC-E2 COC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,055 participants |
| Start Date | 2022-02-17 |
| Est. Completion | 2024-01-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05264506
The ClinicalTrials.gov registry entry for NCT05264506 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 3,055 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Organon and, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NOMAC-E2 COC is the first listed.
NCT05264506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05264506 about?
NCT05264506 is a clinical study titled "Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive". The purpose of this study is evaluating Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive in Premenopausal Females Aged 14 to 35 Years (Inclusive).
What is the current status of trial NCT05264506?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3,055 participants. The study started on 2022-02-17. Estimated completion is 2024-01-26.
What interventions are being tested in trial NCT05264506?
The interventions under investigation include: NOMAC-E2 COC (DRUG).
Who is sponsoring clinical trial NCT05264506?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.